Kenneth S. Canfield, Esq.
Ken joined our patent litigation practice in March 2020, previously having spent over twelve years at a major international firm. He has practiced as a patent attorney since 2006, with a particular focus on patent litigation, as well as experience with post-grant proceedings in the USPTO, advisory work, and prosecution. His litigation experience includes pre-suit investigations, discovery, motion practice, claim construction, trial, post-trial proceedings, and appeal. He has litigated cases in district courts across the country, including the District of Delaware, District of New Jersey, Southern District of New York, Western District of New York, Eastern District of Texas, and others. Ken has worked with a wide variety of technologies, including pharmaceuticals, medical devices, electronics, computers, software, physics, financial instruments, and aseptic food packaging. In the pharmaceutical realm, Ken has litigated a number of Hatch-Waxman cases, including ones concerning Thalomid® (e.g., multiple myeloma), Revlimid® (same), Xyrem® (narcolepsy), Lotronex® (irritable bowel syndrome), Androgel® (testosterone replacement), Kuvan® (phenylketonuria), and OxyContin® (pain). In addition, he has represented companies in post-grant proceedings in the USPTO, including inter partes reviews, post grant reviews, and reexaminations, for pharmaceutical and other technology. His advisory experience includes counseling clients with respect to potential transactions, freedom to operate, and patent validity.
Admissions: Connecticut (2006); New York (2007); registered to practice before U.S. Patent and Trademark Office (2006)
Education: Columbia University School of Law (J.D., 2006) - James Kent Scholar (2004-05, 2005-06); Harlan Fiske Stone Scholar (2003-04)
Yale University (B.S., Physics, 2003) - summa cum laude; Phi Beta Kappa
Practice Areas: Patent Law; Pharmaceutical Patent Law; Patent Litigation, including Hatch-Waxman; Post-Grant Proceedings; Patent Counseling